TICKERNERD
Menu
MCKMCKHealthcare · Medical Distribution

MCK Stock Forecast: McKesson Corp. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$874
+1.73% on the day

The 18 Wall Street analysts covering McKesson Corp. hold a median 12-month price target of $1,000 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$100.1B
Ticker Nerd rank
86 / 100
Median analyst target
$1,000
Analysts covering
18
Revenue$105.4B+7.7% y/y
Operating income$1.4B
Net income$1.0B
Free cash flow−$372.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.6%
1M
+3.9%
YTD
+6.7%
1Y
+27.3%
From 52W high
−12.1%
From 52W low
+29.2%
$676
$995
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MCK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores McKesson Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
86
Growth
83
Quality
74
Revisions
73
Issuance
71
Momentum
61
Accruals
54
Size
3

Volatility (99): The share price has been relatively steady.

Accruals (54): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MCK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MCK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$700$800$900$1,000$1,100Oct 25Jan 26Apr 26Jul 26MCKHigh $1,080Median $1,000Low $845

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
14 Buy4 Hold0 Sell
Low $845Median $1,000High $1,080

The green dot is the last close — the median target sits +14.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
19 Aug 2026BarclaysMaintainsOverweight$925 → $1,000
19 Aug 2026RBC CapitalInitiatesSector Perform$845
11 Aug 2026Wells FargoMaintainsEqual-Weight$812 → $933
11 Aug 2026Wells FargoMaintainsEqual-Weight—
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$860 → $1,000
6 Aug 2026TD CowenMaintainsBuy$989 → $1,006
6 Aug 2026TD CowenMaintainsBuy—
6 Aug 2026UBSMaintainsBuy—
6 Aug 2026UBSMaintainsBuy$1,050 → $1,080
24 July 2026CitigroupMaintainsBuy$945 → $1,000
24 July 2026CitigroupMaintainsBuy—
21 July 2026TD CowenMaintainsBuy$1,012 → $989
21 July 2026TD CowenMaintainsBuy—
10 June 2026BarclaysMaintainsOverweight—
10 June 2026BarclaysMaintainsOverweight$1,050 → $925
14 May 2026CitigroupMaintainsBuy—
12 May 2026Wells FargoMaintainsEqual-Weight—
8 May 2026Evercore ISI GroupMaintainsOutperform—
8 May 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MCK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MCK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, McKesson Corp. returned +27.3% against +19.6% for the S&P 500, dividends included.

MCK vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Oct 25Jan 26Apr 26Jul 26MCKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MCK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.8%
Analysts raising
9
Analysts cutting
1
Fundamentals

McKesson Corp. (MCK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.0×

Cheaper than 34% of US stocks

Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
−78.4×

Cheaper than 99% of US stocks

EV / EBITDA
15.5×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
7.7%

Higher than 46% of US stocks

Earnings growth (YoY)
−21.7%

Higher than 19% of US stocks

Gross margin
3.5%

Higher than 6% of US stocks

Operating margin
1.3%

Higher than 47% of US stocks

Net margin
1.1%

Higher than 50% of US stocks

Returns & dividend
Return on equity
−571.0%

Higher than 3% of US stocks

Return on assets
4.7%

Higher than 75% of US stocks

Dividend yield
0.4%

Higher than 7% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

McKesson Corp. (MCK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • McKesson Corp. has a market value of $100.1B and an enterprise value of $109.7B.

  • Revenue in the twelve months to 30 June 2026: $411.0B. The latest quarter grew 7.7% year on year.

  • Net income over the same four quarters: $5.3B, a 1.3% net margin.

  • Diluted earnings per share, trailing twelve months: $37.37.

  • Free cash flow in the twelve months to 30 June 2026: $6.1B, after $271.0M of capital spending.

  • McKesson Corp. spent $6.7B on share buybacks and $393.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 116.0M.

  • Trailing P/E: 23.0×; forward P/E: 17.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.38%, paying out 9% of earnings.

  • McKesson Corp. employs 41,600 people — $9.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

MCK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
MCKMcKesson Corp.$100.1B
86
CORCencora, Inc.$61.7B
68
CAHCardinal Health, Inc.$54.5B
96
HSICHenry Schein, Inc.$10.2B
80
HCAHCA Healthcare, Inc.*$92.9B
68
ELVElevance Health, Inc.*$89.0B
66
REGNRegeneron Pharmaceuticals, Inc.*$87.6B
93

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own McKesson Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MCK news & analysis

McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate

Zacks Investment Research · 24 Aug 2026positive

McKesson raised its fiscal 2027 earnings-per-share guidance, citing accelerated profit growth driven by oncology, GLP-1 volumes, and specialty distribution, despite cash-flow pressure.

Why it matters — A raised fiscal 2027 EPS outlook tied to oncology and GLP-1 growth signals continued momentum in McKesson's core specialty and distribution businesses, though cash-flow pressure remains a factor to watch.

Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?

Zacks Investment Research · 24 Aug 2026neutral

Zacks discusses whether McKesson stock is worth buying, highlighting the company's double-digit earnings growth, specialty expansion, and capital returns while noting that its premium valuation leaves less room for error.

Why it matters — MCK watchers would care because the piece weighs the company's strong fundamentals against the risk introduced by its elevated valuation.

Allspring Large Cap Growth Fund Q2 2026 Performance Update

Seeking Alpha · 14 Aug 2026negative

Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index in Q2 2026. McKesson Corp. was cited among the fund's detractors for the quarter, along with KLA Corp., Advanced Micro Devices, AstraZeneca and Netflix, while Micron Technology and Snowflake were among contributors.

Why it matters — McKesson watchers would note that the company's stock weighed on a major growth fund's quarterly performance, indicating it lagged during the period.

Here's Why McKesson (MCK) is a Strong Momentum Stock

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research highlights McKesson (MCK) as a strong momentum stock, citing the Zacks Style Scores as a way to identify market-beating stocks for investment portfolios.

Why it matters — MCK watchers would note that the stock is being recognized for strong momentum characteristics by an investment research firm.

McKesson Q1 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

McKesson reported fiscal first-quarter 2027 results that exceeded its expectations, driven by broad-based momentum across its businesses. The company subsequently raised its full-year adjusted earnings outlook.

Why it matters — An earnings beat and a raised full-year outlook signal that McKesson's operating momentum is stronger than anticipated, which is a key indicator for investors tracking the company's financial trajectory.

FAQ

Frequently asked questions about MCK stock

What is the MCK stock price forecast for 2026-2027?

The 18 Wall Street analysts covering McKesson Corp. have a median 12-month price target of $1,000, with estimates ranging from $845 to $1,080. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MCK stock a buy right now?

Of the 18 analysts covering McKesson Corp., 14 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks McKesson Corp. 86 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MCK?

As at 22 Aug 2026, McKesson Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will MCK stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks McKesson Corp. 86 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MCK stock forecast for 2030?

No analyst covering McKesson Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $845 to $1,080 over the next 12 months.

How has MCK stock performed over the past year?

McKesson Corp. returned +27.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does McKesson Corp. do?

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings.

What is the latest news on MCK?

The most recent item we track (Zacks Investment Research, 24 Aug 2026): "McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate". McKesson raised its fiscal 2027 earnings-per-share guidance, citing accelerated profit growth driven by oncology, GLP-1 volumes, and specialty distribution, despite cash-flow pressure.

Company

About McKesson Corp.

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings. Its pharmaceutical distribution business supplies branded, generic, specialty, biosimilar, and over-the-counter products, while its medical-surgical operations provide clinical supplies, logistics, and equipment support. McKesson also offers technology-enabled services that help healthcare organizations manage prescriptions, practice operations, and patient care workflows. Through its broad distribution network and service platforms, McKesson plays a central role in connecting manufacturers, providers, and pharmacies across the U.S. and internationally.

CEO Mr. Brian S. Tyler Ph.D. · 41,600 employees · United States · https://www.mckesson.com